பாரத் ஜுன்ஜுன்வாலா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பாரத் ஜுன்ஜுன்வாலா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பாரத் ஜுன்ஜுன்வாலா Today - Breaking & Trending Today

Impose Exit Tax on fleeing rich


Impose Exit Tax on fleeing rich
Impose Exit Tax on fleeing rich
Bharat Jhunjhunwala
Consultancy company Henley and Partners assists the rich to migrate from one country to another. It has said that the numbers of rich wanting to migrate out of India have increased by 63 percent in 2020. Certainly there is contribution of the Covid pandemic. However, in 2018, before the pandemic, the Afro Asian Bank in its Global Wealth Migration Review reported that 15,000 rich persons migrated out of China, 7,000 from Russia, 5,000 from India and 4,000 from Turkey. Three of these four countries namely, China, Russia and Turkey are dictatorial in their political setup. We may speculate that the out migration from these countries could be due to political suffocation. The inclusion of democratic India in this list is ringing a danger bell for us. On the other hand, the destination of the rich was 12,000 to Australia, 10,000 to the United States, 4,000 to Canada and more importantly 100 ....

United States , Uttar Pradesh , Bharat Jhunjhunwala , Pay Commission , Indian Institute Of Religions , Afro Asian Bank , Global Wealth Migration Review , Avendus Wealth Management , Fifth Pay Commission , Prime Minister , United Sates , ஒன்றுபட்டது மாநிலங்களில் , உத்தர் பிரதேஷ் , பாரத் ஜுன்ஜுன்வாலா , செலுத்த தரகு , உலகளாவிய செல்வம் இடம்பெயர்வு விமர்சனம் , அவென்ட்ஸ் செல்வம் மேலாண்மை , ஐந்தாவது செலுத்த தரகு , ப்ரைம் அமைச்சர் ,

WTO versus Humankind?


WTO versus Humankind?
Bharat Jhunjhunwala
In the main two vaccines are available to us today Covishield developed by AstraZeneca and produced under its license by Serum Institute of India; and Covaxin developed by Bharat Biotech. Serum Institute has to pay one-half of the sale price to AstraZeneca as royalty; or it has to pay Rs 75 as royalty if it sells Covishield to the Central Government at Rs 150. Serum Institute says that it is not economic for it to produce Covishield in the balance Rs 75. For this reason, they have offered to sell Covishield only at Rs 300 to the States and at a higher price to the private buyers. In this way the States will be buying Covishield at Rs 300 and subsidizing the purchase by Center at Rs 150. The Center should act as father of the States. Instead it is acting as their opponent. This is a minor problem, however. Serum Institute is having to pay this huge amount of royalty because we have accepted Product Patents under the World Trade Orga ....

United States , Bharat Jhunjhunwala , World Trade Organization , Tv Program , Drug Companies , Indian Company Bharat Biotech , Serum Institute , Serum Institute Of India , Center At Rs , Central Government , Product Patents , Process Patents , Bharat Biotech , Multinational Corporations , Developed Countries , Formerly Professor , ஒன்றுபட்டது மாநிலங்களில் , பாரத் ஜுன்ஜுன்வாலா , உலகம் வர்த்தகம் ஆர்கநைஸேஶந் , தொலைக்காட்சி ப்ரோக்ர்யாம் , மருந்து நிறுவனங்கள் , சீரம் நிறுவனம் , சீரம் நிறுவனம் ஆஃப் இந்தியா , மைய அரசு , ப்ராடக்ட் காப்புரிமைகள் , பாரத் பயோடெக் ,